In obese mice, stopping incretin-based drugs causes weight to return, but previous treatment with bimagrumab ensures that the regained weight consists more of muscle than fat.
See the scientific wording
In obese mice, withdrawal of incretin-based therapeutics results in weight regain, and prior treatment with bimagrumab prevents preferential accrual of fat mass while promoting regain of lean mass during this rebound weight gain.
Correlational — new studies may shift this
ObservationalOne low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
2180-LB: Bimagrumab Augments Metabolic Rate to Improve Incretin-Induced Weight Loss in Obese Mice
Cohort StudyAnimal
When obese mice stopped taking weight-loss drugs, they usually regained fat — but if they had taken bimagrumab before, they regained muscle instead. The study found exactly that.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
When a person stops taking weight-loss drugs, the body usually regains fat. But if they previously took a drug that blocks ACVR2A/B receptors, their body burns more calories as heat instead of storing fat, so they regain muscle instead of fat.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In obese mice, stopping incretin-based drugs causes weight to return, but previous treatment with bimagrumab ensures that the regained weight consists more of muscle than fat.
Mechanism
1 studyBlocking ACVR2A/B receptors makes fat tissue burn more calories as heat. When weight comes back after stopping a weight-loss drug, this heat production uses up extra calories instead of letting them turn into fat, so the body rebuilds muscle instead.
When a person stops taking weight-loss drugs, the body usually regains fat. But if they previously took a drug that blocks ACVR2A/B receptors, their body burns more calories as heat instead of storing fat, so they regain muscle instead of fat.
ACVR2A/B receptors in adipose tissue are blocked by an antagonist, preventing signaling from myostatin, activin, and related ligands
Loss of ACVR2A/B signaling removes suppression of thermogenic gene programs in adipose tissue
Thermogenic gene activation increases mitochondrial uncoupling and heat production in adipose tissue
Elevated energy expenditure creates a sustained negative energy balance during weight rebound
Negative energy balance preferentially spares lean tissue and redirects nutrient partitioning toward muscle synthesis instead of fat storage
Evidence from Studies
Supporting (1)
Community contributions welcome
When obese mice stopped taking weight-loss drugs, they usually regained fat — but if they had taken bimagrumab before, they regained muscle instead. The study found exactly that.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Bimagrumab and Incretin Withdrawal Effects on Body Composition in Obese Mouse Models
Population: Obese mouse models; Intervention: Prior bimagrumab administration; Comparator: Placebo or no prior bimagrumab; Outcome: Fat mass and lean mass changes during and after incretin-based therapeutic withdrawal; Duration: Throughout treatment and rebound phases.
Double-Blind Randomized Trial of Bimagrumab vs Placebo on Body Composition During Incretin Withdrawal in Obese Mice
Population: Obese mice; Intervention: Bimagrumab pretreatment; Comparator: Placebo pretreatment; Outcome: Fat mass and lean mass changes during and after incretin withdrawal; Duration: Pre-treatment, treatment, withdrawal, and rebound phases (minimum 8 weeks post-withdrawal).
Longitudinal Cohort Study of Body Composition Trajectories in Obese Mice Following Incretin Withdrawal with and Without Prior Bimagrumab
Population: Obese mice; Intervention: Prior bimagrumab exposure (yes/no); Comparator: Non-exposed cohort; Outcome: Serial measurements of fat and lean mass during and after incretin withdrawal; Duration: Continuous monitoring from pretreatment through 12 weeks post-withdrawal.
Mechanistic Animal Study of Bimagrumab's Effect on Muscle and Fat Tissue Remodeling During Incretin Withdrawal in Obese Mice
Population: Obese mice; Intervention: Bimagrumab pretreatment followed by incretin withdrawal; Comparator: Incretin withdrawal without bimagrumab; Outcome: Histological, molecular, and metabolic markers in adipose and skeletal muscle tissue; Duration: 4–8 weeks post-withdrawal.
In Vitro Analysis of Bimagrumab's Effect on Adipocyte and Myoblast Differentiation Under Incretin Deprivation Conditions
Population: Primary adipocytes and myoblasts from obese mice; Intervention: Bimagrumab exposure under incretin-deprived conditions; Comparator: No bimagrumab under same conditions; Outcome: Lipid content, myogenic marker expression, and metabolic activity; Duration: 7–14 days.